(Project 2 ? Orthodontic Trial in OI) Our previous studies have shown that approximately 80% of individuals with osteogenesis imperfecta (OI) type III and IV (the moderate to severe forms of OI) have dental malocclusion. This is a major unmet medical need as malocclusion interferes with speech, the ability to chew and detrimentally impacts on the quality of life. There are no evidence-based treatment options for malocclusion in OI. In our clinical practice we have treated malocclusion in 3 adolescents with OI types III and IV using Invisalign, a widely used FDA- approved approach to treat malocclusion (Class II device). Invisalign is typically used to treat adolescents or young adults with malocclusion of intermediate severity. The severity of malocclusion can be determined using the Peer Assessment Rating (PAR) score. PAR scores between 15 and 40 are considered intermediate severity. We propose to perform a multicenter study to evaluate the efficacy and safety of Invisalign for the treatment of malocclusion in OI. We will assess the improvement in malocclusion in a 6-month randomized study, followed by an open-label extension study that evaluates the outcome of a full 24-months Invisalign treatment course.
Aim 1 is to determine whether 6 months of treatment with the Invisalign system improves the malocclusion compared to an untreated control group (randomized trial). We will enroll individuals with OI type III or IV from 12 to 40 years of age who have malocclusion of intermediate severity. Subjects will be assigned to either receive Invisalign treatment (treatment group) or to be followed without orthodontic treatment (control group) (n = 18 per group). Randomization will be stratified according to OI type, age and bisphosphonate treatment status. The primary endpoint will be the change in PAR score; secondary endpoints will include anatomical tooth movement. The hypothesis is that the treatment will induce tooth movement and have a significantly larger decrease in mean PAR score (indicating improved malocclusion) than the control group.
Aim 2 of the study is to determine whether a full treatment course of Invisalign treatment improves oral-health related quality of life (extension study). After the first 6 months of randomized therapy, all participants will have Invisalign treatment. The total treatment period will be 24 months (+/- 6 months, based on achieving the treatment goals specified at baseline). The primary study endpoint will be change in oral-health related quality of life. Secondary endpoints will be changes in mastication, expressed anatomically as the number of occlusal contacts, and masticatory efficiency, a functional parameter, as well as patient satisfaction. The hypothesis is that oral health-related quality of life and mastication will improve over the Invisalign treatment course. This study will provide for the first time scientific evidence on how to treat malocclusion in the context of OI. If successful, this approach can be rapidly implemented into clinical practice.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AR068069-07
Application #
10017036
Study Section
Special Emphasis Panel (ZTR1)
Project Start
2014-08-06
Project End
2024-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Alhamdi, Shatha; Lee, Yi-Chien; Chowdhury, Shimul et al. (2018) Heterozygous WNT1 variant causing a variable bone phenotype. Am J Med Genet A 176:2419-2424
Dagdeviren, Didem; Tamimi, Faleh; Lee, Brendan et al. (2018) Dental and craniofacial characteristics caused by the p.Ser40Leu mutation in IFITM5. Am J Med Genet A :
Jain, Mahim; Tam, Allison; Shapiro, Jay R et al. (2018) Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study. Genet Med :
Najirad, Mohammadamin; Ma, Mang Shin; Rauch, Frank et al. (2018) Oral health-related quality of life in children and adolescents with osteogenesis imperfecta: cross-sectional study. Orphanet J Rare Dis 13:187
Tam, Allison; Chen, Shan; Schauer, Evan et al. (2018) A multicenter study to evaluate pulmonary function in osteogenesis imperfecta. Clin Genet 94:502-511
Lim, Joohyun; Grafe, Ingo; Alexander, Stefanie et al. (2017) Genetic causes and mechanisms of Osteogenesis Imperfecta. Bone 102:40-49
Lietman, Caressa D; Lim, Joohyun; Grafe, Ingo et al. (2017) Fkbp10 Deletion in Osteoblasts Leads to Qualitative Defects in Bone. J Bone Miner Res 32:1354-1367
Grafe, Ingo; Alexander, Stefanie; Yang, Tao et al. (2016) Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta. J Bone Miner Res 31:1030-40
Bellur, S; Jain, M; Cuthbertson, D et al. (2016) Cesarean delivery is not associated with decreased at-birth fracture rates in osteogenesis imperfecta. Genet Med 18:570-6
Lietman, Caressa D; Marom, Ronit; Munivez, Elda et al. (2015) A transgenic mouse model of OI type V supports a neomorphic mechanism of the IFITM5 mutation. J Bone Miner Res 30:489-98